MoonLake Immunotherapeutics - Class A

Research MoonLake Immunotherapeutics - Class A (MLTX) on Bullrun: market cap USD 1.47B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMLTX
• ExchangeNASDAQ
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.47B
• Financial periodFY2025
• Net income-USD 227.32M
• Free cash flow-USD 196.04M

Valuation Snapshot

latest market cap is USD 1.47B.

About MoonLake Immunotherapeutics - Class A

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Frequently asked questions

What is MoonLake Immunotherapeutics - Class A's market cap?

MoonLake Immunotherapeutics - Class A's market capitalization is USD 1.47B.

What does MoonLake Immunotherapeutics - Class A do?

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.